Duke Signs Exclusive Licensing Agreement with Leading Genome Editing Company

Duke University has signed an exclusive licensing agreement with Editas Medicine, a leading genome editing company, for genetic engineering technologies developed in the lab of Charles Gersbach, assistant professor of biomedical engineering. The agreement focuses on Gersbach’s work with genome engineering technologies known as CRISPR/Cas9 and TALENs.